302 related articles for article (PubMed ID: 15170171)
1. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
[TBL] [Abstract][Full Text] [Related]
2. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
3. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M
Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536
[TBL] [Abstract][Full Text] [Related]
4. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
Flohr T; Hess G; Kolbe K; Gamm H; Nolte H; Stanislawski T; Huber C; Derigs HG
Bone Marrow Transplant; 2002 May; 29(9):769-75. PubMed ID: 12040475
[TBL] [Abstract][Full Text] [Related]
6. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
[TBL] [Abstract][Full Text] [Related]
7. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
Lazzarino M; Arcaini L; Bernasconi P; Alessandrino EP; Gargantini L; Cairoli R; Orlandi E; Astori C; Brusamolino E; Pagnucco G; Colombo AA; Calatroni S; Iacona I; Regazzi MB; Morra E
Br J Haematol; 2002 Jan; 116(1):229-35. PubMed ID: 11841421
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma.
Endo T; Sato N; Mogi Y; Koizumi K; Nishio M; Fujimoto K; Sakai T; Kumano K; Obara M; Ikeda H; Koike T
Bone Marrow Transplant; 2004 Apr; 33(7):703-7. PubMed ID: 14743197
[TBL] [Abstract][Full Text] [Related]
9. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
[TBL] [Abstract][Full Text] [Related]
10. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation.
Cairoli R; Grillo G; Tedeschi A; D'Avanzo G; Marenco P; Morra E
Haematologica; 2004 Mar; 89(3):361-3. PubMed ID: 15020279
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of sequential high-dose chemotherapy with in vivo rituximab-purged stem cell autografting for mantle cell lymphoma].
Takasaki H; Hashimoto C; Takemura S; Motomura S; Ishigatsubo Y
Rinsho Ketsueki; 2010 Jan; 51(1):57-62. PubMed ID: 20134141
[TBL] [Abstract][Full Text] [Related]
12. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma.
Friedberg JW; Kim H; Li S; Neuberg D; Boyd K; Daley H; Fisher DC; Gribben JG; Spitzer T; Freedman AS
Bone Marrow Transplant; 2003 Oct; 32(7):681-6. PubMed ID: 13130315
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
Berinstein NL; Buckstein R; Imrie K; Spaner D; Mangel J; Tompkins K; Pennell N; Reis M; Pavlin P; Lima A; Couvadia A; Robinson J; Richardson P
Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S14-7. PubMed ID: 11840156
[TBL] [Abstract][Full Text] [Related]
15. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Voso MT; Pantel G; Weis M; Schmidt P; Martin S; Moos M; Ho AD; Haas R; Hohaus S
Br J Haematol; 2000 Jun; 109(4):729-35. PubMed ID: 10929022
[TBL] [Abstract][Full Text] [Related]
16. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinical practice.
Vantelon JM; Koscielny S; Brault P; Bourhis JH; Ribrag V; Pico J; Fenaux P; Munck JN
Bone Marrow Transplant; 2000 Mar; 25(5):495-9. PubMed ID: 10713625
[TBL] [Abstract][Full Text] [Related]
17. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
Kamezaki K; Kikushige Y; Numata A; Miyamoto T; Takase K; Henzan H; Aoki K; Kato K; Nonami A; Kamimura T; Arima F; Takenaka K; Harada N; Fukuda T; Hayashi S; Ohno Y; Eto T; Harada M; Nagafuji K
Bone Marrow Transplant; 2007 May; 39(9):523-7. PubMed ID: 17369863
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
19. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
[TBL] [Abstract][Full Text] [Related]
20. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.
Gianni AM; Cortelazzo S; Magni M; Martelli M;
Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S10-3. PubMed ID: 11840155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
